Lytix Biopharma: Annual Report for 2022
Oslo, Norway, March 30, 2023 – Lytix Biopharma AS (“Lytix”) (Euronext Growth Oslo: LYTIX), a clinical stage immuno-oncology company, announces that it has published its Annual Report for 2022, which was approved by the board of directors on March 29, 2023.
“In the course of 2022, our unique position in the immune-oncology field has been confirmed. We bring a novel immunotherapy approach to the table that addresses the most fundamental challenge in current immunotherapy: tumor heterogeneity,” says Øystein Rekdal, CEO of Lytix Biopharma.
The Annual Report for 2022 is attached to this notice and is also available on the company’s website, www.lytixbiopharma.com, under Investors.
For more information, please contact:
Gjest Breistein, CFO: gjest.breistein@lytixbiopharma.com
Ole Peter Nordby, Head of IR & Communication Manager: ole.peter.nordby@lytixbiopharma.com
Lytix in brief:
Based in Oslo, Norway, Lytix Biopharma is a clinical stage immuno-oncology company developing novel cancer immunotherapies, an area within cancer therapy that is aimed at activating the patient’s immune system to fight cancer. The Company’s technology is based on pioneering research in “host defense peptides” – nature’s first line of defense towards foreign pathogens. Lytix Biopharma’s lead product, LTX-315, is a first-in-class oncolytic molecule representing a new and superior in situ therapeutic vaccination principle to boost anti-cancer immunity, with the potential to be the ideal combination partner with other types of immunotherapy. LTX-315 target cancer cells and disintegrate their cell membranes, causing immunogenic cell death and release of a patient’s tumor specific antigens. This mode of action allows cytotoxic T cells to recognize, infiltrate, and attack cancer cells. The Company was listed on Euronext Growth in Oslo in June 2021, following a private placement covered by investors such as PBM Capital, a US based, healthcare-focused investment firm.